Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Investigation

• Publication date

  2003-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI16198PMID 12782679PMCID PMC156102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteasome inhibitors induce apoptosis in growth hormone- and prolactin-secreting rat pituitary tumor cells.

  2002cited by this paper
• Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

  2001cited by this paper
• The cellular chamber of doom.

  2001cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• The repressor and activator forms of Cubitus interruptus control Hedgehog target genes through common generic gli-binding sites.

  2000cited by this paper
• Hedgehog controls limb development by regulating the activities of distinct transcriptional activator and repressor forms of Cubitus interruptus.

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

  1999cited by this paper
• Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

  1999cited by this paper
• Eponemycin exerts its antitumor effect through the inhibition of proteasome function.

  1999cited by this paper
• Nuclear trafficking of Cubitus interruptus in the transcriptional regulation of Hedgehog target gene expression.

  1999cited by this paper
• Systemic Administration of Acidic Fibroblast Growth Factor (FGF‐1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats

  1999cited by this paper
• High‐Dose Estrogen Induces De Novo Medullary Bone Formation in Female Mice

  1999cited by this paper
• Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

  1999cited by this paper
• Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

  1999cited by this paper
• Sonic Hedgehog-induced Activation of the Gli1Promoter Is Mediated by GLI3*

  1999influential reference
• Stimulation of bone formation in vitro and in rodents by statins.

  1999cited by this paper
• Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α', β'-epoxyketones

  1999cited by this paper
• A mouse model of Greig cephalapolysyndactyly syndrome: the extra-toes J mutation contains an intragenic deletion of the Gli3 gene

  1998cited by this paper
• Transducing Hedgehog: the story so far

  1998cited by this paper
• Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton.

  1998influential reference
• Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

  1998cited by this paper
• 5-Lipoxygenase metabolites inhibit bone formation in vitro.

  1998cited by this paper
• Eponemycin analogues: syntheses and use as probes of angiogenesis.

  1998cited by this paper
• Proteolysis that is inhibited by hedgehog targets Cubitus interruptus protein to the nucleus and converts it to a repressor.

  1997cited by this paper
• New insights into the mechanisms and importance of the proteasome in intracellular protein degradation.

  1997cited by this paper
• Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice.

  1996cited by this paper
• The effects of cytokines and growth factors on osteoblastic cells.

  1995cited by this paper
• Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

  1995cited by this paper
• Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells

  1994cited by this paper
• The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.

  1994cited by this paper
• Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

  1994cited by this paper
• MHC-linked LMP gene products specifically alter peptidase activities of the proteasome

  1993cited by this paper
• Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos.

  1992influential reference
• Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones.

  1987cited by this paper
• Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose.

  1986cited by this paper

• Tetrapeptides derived from black bean enhance osteogenesis and alleviate ovariectomy-induced bone loss via activation of BMP-2/Smad signaling.

  2026cites this paper
• Changing landscape of hematopoietic and mesenchymal cells and their interactions during aging and in age-related skeletal pathologies.

  2025cites this paper
• Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?

  2025cites this paper
• Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

  2025cites this paper
• IRE1α pathway: A potential bone metabolism mediator

  2024cites this paper
• Assessing the effects of probiotic supplementation, single strain versus mixed strains, on femoral mineral density and osteoblastic gene mRNA expression in rats

  2024cites this paper
• An updated overview of the search for biomarkers of osteoporosis based on human proteomics

  2024cites this paper
• Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study

  2024cites this paper
• Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.

  2023cites this paper
• Targeting proteostasis network in osteoporosis: pathological mechanisms and therapeutic implications.

  2023cites this paper
• Comparative- and network-based proteomic analysis of bacterial chondronecrosis with osteomyelitis lesions in broiler’s proximal tibiae identifies new molecular signatures of lameness

  2023cites this paper
• Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

  2023cites this paper
• Carcass composition, meat quality, leg muscle status, and its mRNA expression profile in broilers affected by valgus-varus deformity

  2023cites this paper
• Myeloid CCN3 protects against aortic valve calcification

  2023cites this paper
• Translational Strategies to Target Metastatic Bone Disease

  2022cites this paper
• Proteasome inhibition-enhanced fracture repair is associated with increased mesenchymal progenitor cells in mice

  2022cites this paper
• E3 Ubiquitin Ligases: Potential Therapeutic Targets for Skeletal Pathology and Degeneration

  2022cites this paper
• Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

  2022cites this paper
• Inhibition of Neddylation Suppresses Osteoclast Differentiation and Function In Vitro and Alleviates Osteoporosis In Vivo

  2022cites this paper
• NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?

  2022cites this paper
• Myeloma Bone Disease: A Comprehensive Review

  2021cites this paper
• The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes

  2021cites this paper
• Skeletal Aging and Osteoporosis: Cellular Senescence and Beyond

  2021cites this paper
• Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics

  2021cites this paper
• Mechanisms, Diagnosis and Treatment of Bone Metastases

  2021cites this paper
• Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

  2021cites this paper
• The muscle to bone axis (and viceversa): an encrypted language affecting tissues and organs and yet to be codified?

  2021cites this paper
• Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

  2021cites this paper
• Expression and Role of Ubiquitin-Specific Peptidases in Osteoblasts

  2021cites this paper
• Bone Morphogenetic Protein-2 in Development and Bone Homeostasis

  2020cites this paper
• ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation

  2020cites this paper
• Cell cycle exit during bortezomib‐induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s‐upregulated p21Cip1 and p27Kip1

  2020cites this paper
• Quantitative proteomics and reverse engineer analysis identified plasma exosome derived protein markers related to osteoporosis.

  2020cites this paper
• Identification of key regulators responsible for dysregulated networks in osteoarthritis by large-scale expression analysis

  2020cites this paper
• Emerging therapeutic targets for osteoporosis

  2020cites this paper
• Systems biology analysis of osteogenic differentiation behavior by canine mesenchymal stem cells derived from bone marrow and dental pulp

  2020cites this paper
• Adjuvant drug-assisted bone healing: Part III – Further strategies for local and systemic modulation

  2019cites this paper
• Effect of low‐dose bortezomib on bone formation in smouldering multiple myeloma

  2019cites this paper
• Tyrosine kinase receptor c‐ros‐oncogene 1 inhibition alleviates aberrant bone formation of TWIST‐1 haploinsufficient calvarial cells from Saethre–Chotzen syndrome patients

  2018cites this paper
• The Proteasome and Myeloma-Associated Bone Disease

  2018cites this paper
• Structural determinants and genetic modifications enhance BMP2 stability and extracellular secretion

  2018cites this paper
• An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties

  2018cites this paper
• The Expanding Life and Functions of Osteogenic Cells: From Simple Bone‐Making Cells to Multifunctional Cells and Beyond

  2018cites this paper
• University of Southern Denmark An engineered, quantifiable in vitro model for analysing the effect of proteostasis- targeting drugs on tissue physical properties Loaiza,

  2018cites this paper
• Deubiquitinating Enzymes and Bone Remodeling

  2018cites this paper
• Ubiquitin E3 ligase Itch negatively regulates osteoblast function by promoting proteasome degradation of osteogenic proteins

  2017cites this paper
• Emerging treatment approaches for myeloma-related bone disease

  2017cites this paper
• Ixazomib enhances parathyroid hormone–induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor

  2017cites this paper
• Daidzein promotes proliferation and differentiation in osteoblastic OCT1 cells via activation of the BMP-2/Smads pathway.

  2017cites this paper
• Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma

  2017cites this paper
• Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation

  2017cites this paper
• The utility of bone remodeling markers in the diagnosis, evolution and treatment response evaluation in bone metastases.

  2016cites this paper
• Investigational drugs for fracture healing: preclinical & clinical data

  2016cites this paper
• The effects of proteasome inhibitors on bone remodeling in multiple myeloma.

  2016cites this paper
• Short Anabolic Peptides for Bone Growth

  2016cites this paper
• Proteasome inhibitors, including curcumin, improve pancreatic β-cell function and insulin sensitivity in diabetic mice

  2016cites this paper
• Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma

  2016cites this paper
• Osteoporosis and Mechanisms of Skeletal Aging

  2016cites this paper
• Modulation of NF-κB Signaling as a Therapeutic Target in Autoimmunity

  2016cites this paper
• Melatonin, bone regulation and the ubiquitin-proteasome connection: A review.

  2016cites this paper
• The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors

  2016influential citation
• Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases

  2016cites this paper
• Daidzein promotes osteoblast proliferation and differentiation in OCT1 cells through stimulating the activation of BMP-2/Smads pathway.

  2016cites this paper
• Siah2 Protein Mediates Early Events in Commitment to an Adipogenic Pathway*

  2016cites this paper
• Anabolic actions of Notch on mature bone

  2016cites this paper
• Role of Gli3 during intramembranous calvarial bone development

  2015cites this paper
• Multiple myeloma-related bone disease: state-of-art and next future treatments

  2015cites this paper
• Impact of the Uremic Milieu on the Osteogenic Potential of Mesenchymal Stem Cells

  2015cites this paper
• Synergistic effects of dimethyloxalylglycine and butyrate incorporated into α-calcium sulfate on bone regeneration.

  2015cites this paper
• High‐dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma

  2015cites this paper
• Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

  2015cites this paper
• Say-Meyer syndrome: additional manifestations in a new patient and phenotypic assessment

  2015cites this paper
• Probiotics (Bifidobacterium longum) Increase Bone Mass Density and Upregulate Sparc and Bmp-2 Genes in Rats with Bone Loss Resulting from Ovariectomy

  2015cites this paper
• Characterization of the 26S Proteasome S7 Subunit Gene and Its Expression during Regeneration in Apostichopus japonicus

  2015cites this paper
• E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models

  2015cites this paper
• Local application of a proteasome inhibitor enhances fracture healing in rats

  2015cites this paper
• Turning Bone Morphogenetic Protein 2 (BMP2) on and off in Mesenchymal Cells

  2015influential citation
• Targeting the bone marrow microenvironment in multiple myeloma

  2015cites this paper
• Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

  2015cites this paper
• A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice

  2015cites this paper
• Proteasome inhibitors blunt myeloma induced osteocyte death targeting autophagy both in vitro and in vivo in multiple myeloma patients

  2015cites this paper
• The use of animal models in multiple myeloma.

  2015cites this paper
• Engineered nanomedicine for myeloma and bone microenvironment targeting

  2014cites this paper
• Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2.

  2014cites this paper
• Novel therapeutic targets in myeloma bone disease

  2014cites this paper
• Structure-based design and synthesis of bimodal proteasome inhibitors as therapeutic agents

  2014cites this paper
• Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.

  2014cites this paper
• Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma

  2014cites this paper
• Bone Cell Senescence: Mechanisms and Perspectives

  2014cites this paper
• Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies

  2014cites this paper
• Bone Disease in Multiple Myeloma: Pathophysiology and Management

  2014cites this paper
• Bone Disease in Multiple Myeloma: Pathophysiology and Management

  2014cites this paper
• A Comprehensive Review on the Role of Various Materials in the Osteogenic Differentiation of Mesenchymal Stem Cells with a Special Focus on the Association of Heat Shock Proteins and Nanoparticles

  2014cites this paper
• Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options

  2014cites this paper
• Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.

  2014cites this paper
• Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.

  2014cites this paper
• The effects of bortezomib on bone disease in patients with multiple myeloma

  2014cites this paper
• The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

  2013cites this paper
• The Effect of Novel Anti-myeloma Agents on Bone Metabolism

  2013cites this paper
• Effects of Proteasome inhibitors on chondrogenesis and Linear bone growth

  2013cites this paper